Hologic completes $79-per-share sale to Blackstone and TPG

Hologic says its acquisition by funds managed by Blackstone and TPG has closed, taking the diagnostics and women’s health company private.

In an April 7 announcement, the company said stockholders will receive $76 in cash plus a contingent value right worth up to $3 per share, for total consideration of up to $79 per share. Hologic said its common stock has ceased trading and will be delisted from Nasdaq.

The company also said José E. Almeida, known as Joe Almeida, has been named chief executive officer effective immediately.

The deal was first announced in October 2025 and later approved by Hologic stockholders in February. The SEC filing accompanying the closing said the merger was completed on April 7, 2026, with Hologic becoming a wholly owned subsidiary of the buyer group.

The contingent value right is tied to future Hologic Breast Health revenue goals in fiscal 2026 and 2027, so the final value to shareholders will depend on whether those targets are met.

The closing ends Hologic’s run as a public company and hands control to the private-equity buyers that agreed to the transaction last year.